Xeris Biopharma Holdings, Inc.
XERSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 6, 2026 | Barclays | Jenna Davidner | $14.00(+38%) | $10.13 | TheFly |
| Sep 10, 2026 | Leerink Partners | Roanna Ruiz | $16.00(+108%) | $7.71 | TheFly |
| Aug 20, 2026 | Barclays | $12.00(+37%) | $8.78 | TheFly | |
| Dec 8, 2025 | Barclays | $9.00(+29%) | $6.99 | TheFly | |
| Oct 29, 2025 | Oppenheimer | Leland Gershell | $18.00(+81%) | $9.97 | TheFly |
| Mar 7, 2025 | Piper Sandler | $4.00(-6%) | $4.24 | TheFly | |
| Nov 11, 2024 | H.C. Wainwright | Oren Livnat | $6.60(+103%) | $3.25 | StreetInsider |
| Oct 23, 2024 | Oppenheimer | Leland Gershell | $5.00(+66%) | $3.02 | StreetInsider |
| May 10, 2024 | Piper Sandler | David Amsellem | $3.00(+62%) | $1.85 | StreetInsider |
| Apr 28, 2022 | Craig-Hallum | $6.50(+179%) | $2.33 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Oppenheimer | maintain | Outperform | Nov 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 6, 2026 |
| Piper Sandler | maintain | Neutral | Nov 6, 2026 |
| Barclays | maintain | Overweight | Oct 6, 2026 |
| Leerink Partners | maintain | Outperform | Sep 10, 2026 |
| Barclays | maintain | Overweight | Aug 20, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 2, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 9, 2026 |
| Oppenheimer | maintain | Outperform | Nov 7, 2025 |
| Piper Sandler | maintain | Neutral | Nov 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 7, 2025 |
| Oppenheimer | maintain | Outperform | Oct 29, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 17, 2025 |
| Leerink Partners | maintain | Outperform | Aug 19, 2025 |
| Craig-Hallum | maintain | Buy | Aug 8, 2025 |
| Oppenheimer | maintain | Outperform | Aug 8, 2025 |
| Leerink Partners | maintain | Outperform | Jun 5, 2025 |
| Oppenheimer | maintain | Outperform | May 9, 2025 |
| Piper Sandler | maintain | Neutral | Mar 7, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 7, 2025 |
| Craig-Hallum | maintain | Buy | Mar 7, 2025 |
| Leerink Partners | maintain | Outperform | Mar 7, 2025 |
| Jefferies | maintain | Buy | Jan 29, 2025 |
| Piper Sandler | downgrade | Overweight →Neutral | Nov 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 11, 2024 |
Earnings History
Next report: Mar 1, 2027 · EPS est. $0.03| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $0.06 | $0.03 | $107.2M | $101.7M |
| Aug 6, 2026 | $-0.18 | $0.01 | $91.0M | $90.1M |
| May 7, 2026 | $0.01 | $-0.00 | $82.5M | $79.8M |
| Mar 2, 2026 | $0.06 | $0.03 | $85.8M | $82.2M |
| Nov 6, 2025 | $0.00 | $0.01 | $74.4M | $86.0M |
| Aug 7, 2025 | $-0.01 | $-0.03 | $71.5M | $72.3M |
| May 8, 2025 | $-0.06 | $-0.07 | $60.1M | $57.6M |
| Mar 6, 2025 | $-0.03 | $-0.08 | $60.1M | $54.9M |
News
Xeris Biopharma NASDAQ: XERS raised its 2026 revenue guidance and its 2030 outlook after third-quarter sales increased 44% year over year, driven by rapid growth in its Cushing syndrome treatment Recorlev.
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) shares hit a new 52-week high during trading on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $12.11 and last traded at $12.8150, with a volume of 122,067 shares trading hands. The stock had previously closed at $10.46.
Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Cristi Barnett - Vice President of Investor Relations John Shannon - Chairman & CEO Steven Pieper - Chief Financial Officer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, …
Xeris Biopharma (XERS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.
Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced its financial results and business highlights for the third quarter ended September 30, 2026. “As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve tha.
Cocrystal Pharma (NASDAQ: COCP - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Volatility and Risk Cocrystal Pharma has a
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced the appointment of Menassie M. Taddese to its Board of Directors, effective today. Taddese will also serve on the Board's Audit Committee. “We are delighted to welcome Menassie to the Xeris Board,” said John Shannon, Chairman a.
On October 23, 2026, Xeris Biopharma Holdings Inc (XERS) shares fell 6.1% to a current price of $10.20, within a 52-week range of $5.25 to $11.42. This price mo
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call.
Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Institutional and Insider Ownership 77.4% of Organon
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REINFORCES LEADERSHIP IN ENDOCRINOLOGY WITH DATA DISCLOSURES SPANNING COMMERCIAL PORTFOLIO & PIPELINE AT MULTIPLE SCIENTIFIC MEETINGS.
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Institutional and Insider Ownership 42.7% of Xeris Biopharma
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2026, the Compensation Committee of Xeris' Board of Directors granted non-qualified stock options and restricted stock units for an aggregate of 352,170 shares of its common stock to 60 new employees under Xeris' Inducement Equity …
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) traded up 5.2% during mid-day trading on Monday. The company traded as high as $9.38 and last traded at $9.5750. Approximately 460,484 shares changed hands during trading, a decline of 75% from the average daily volume of 1,858,300 shares. The stock had previously closed at $9.10.
Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported on Tuesday, citing people familiar with the matter.
Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript